Lastly, double blockade of IL-17A and IL-17F (bimekizumab) in RA patients with an inadequate TNF-α response has been shown to achieve a greater reduction of DAS28-CRP at week 20 relative to comparable patients receiving a placebo [115]. The gene discussed is IL17A; the disease is rheumatoid arthritis.